For most of GLP-1's research life, the receptor was studied in isolation. A peptide engaged the receptor; insulin was secreted; gastric emptying slowed; satiety pathways activated centrally. The pharmacology was clean, the readouts were reproducible, and the field had a working consensus by the late 2010s.
What changed with tirzepatide was not the receptor — it was the architecture of the molecule. By engineering a single peptide that engages both the GLP-1 and GIP receptors, the field moved from agonism to co-agonism, and the consequences went well beyond the sum of the parts.
What dual agonism does that single agonism doesn't
In published in-vitro work, the addition of GIP receptor activity does not simply layer on a second insulin-secretion signal. It changes the kinetics of the GLP-1 response itself. Beta-cell sensitivity shifts. Adipose tissue, which expresses the GIP receptor at meaningful density, becomes a participant in the response rather than a bystander.
Why this matters for research design
If you are designing a study with tirzepatide, treating it as a higher-dose semaglutide is the most common error. The pharmacology is qualitatively different, not quantitatively different.
